FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Juan Carlos Lacal

Research Profile

Chemicals & Drugs

Living Beings

Mouse

Physiology

Anatomy

Disorders

Occupations

Drug Design

Co-author Network

Publications

TOP 3
Juan Casado-Vela; Juan Carlos Lacal; Felix Elortza
Protein chimerism: novel source of protein diversity in humans adds complexity to bottom-up proteomics.
Juan Casado-Vela; Arancha Cebrián; María Teresa Gómez del Pulgar; Juan Carlos Lacal
Approaches for the study of cancer: towards the integration of genomics, proteomics and metabolomics.
Juan Casado-Vela; Arancha Cebrián; Nestor Alvarez-Ayerza; Teresa Gómez del Pulgar; Juan Carlos Lacal
Human urine proteomics: building a list of human urine cancer biomarkers.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Juan Carlos Lacal (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Juan Casado-Vela; Juan Carlos Lacal; Felix Elortza
Protein chimerism: novel source of protein diversity in humans adds complexity to bottom-up proteomics.
Proteomics 2013;13(1):5-11.
2011: Juan Casado-Vela; Arancha Cebrián; María Teresa Gómez del Pulgar; Juan Carlos Lacal
Approaches for the study of cancer: towards the integration of genomics, proteomics and metabolomics.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2011;13(9):617-28.
2011: Juan Casado-Vela; Arancha Cebrián; Nestor Alvarez-Ayerza; Teresa Gómez del Pulgar; Juan Carlos Lacal
Human urine proteomics: building a list of human urine cancer biomarkers.
Expert review of proteomics 2011;8(3):347-60.
2011: David Gallego-Ortega; Fátima Valdés-Mora; Arancha Cebrián; Teresa Gómez del Pulgar; Juan Carlos Lacal
Involvement of human choline kinase alpha and beta in carcinogenesis: a different role in lipid metabolism and biological functions.
Advances in enzyme regulation 2011;51(1):183-94.
2010: Nada M S Al-Saffar; L Elizabeth Jackson; Florence I Raynaud; Paul A Clarke; Ana Ramírez de Molina; Juan Carlos Lacal; Paul Workman; Martin Leach
The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.
Cancer research 2010;70(13):5507-17.
2009: Boon Tin Chua; David Gallego-Ortega; Ana Ramirez de Molina; Axel Ullrich; Juan Carlos Lacal; Julian Downward
Regulation of Akt(ser473) phosphorylation by choline kinase in breast carcinoma cells.
Molecular cancer 2009;8():131.
2009: David Gallego-Ortega; Ana Ramirez de Molina; Maria Angeles Ramos; Fatima Valdes-Mora; Maria Gonzalez Barderas; Jacinto Sarmentero-Estrada; Juan Carlos Lacal
Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment.
PloS one 2009;4(11):e7819.
2009: Fátima Valdés-Mora; Teresa Gómez del Pulgar; Eva Bandrés; Paloma Cejas; Ana Ramírez de Molina; Rosa Pérez-Palacios; David Gallego-Ortega; Miguel Angel García-Cabezas; Enrique Casado; Javier Larrauri; Manuel Nistal; Manuel González Barón; Jesús García-Foncillas; Juan Carlos Lacal
TWIST1 overexpression is associated with nodal invasion and male sex in primary colorectal cancer.
Annals of surgical oncology 2009;16(1):78-87.
2008: Teresa Gómez del Pulgar; Fátima Valdés-Mora; Eva Bandrés; Rosa Pérez-Palacios; Carolina Espina; Paloma Cejas; Miguel Angel García-Cabezas; Manuel Nistal; Enrique Casado; Manuel González Barón; Jesús García-Foncillas; Juan Carlos Lacal
Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism.
International journal of oncology 2008;33(1):185-93.
2008: Ana Ramírez de Molina; David Gallego-Ortega; Jacinto Sarmentero-Estrada; David Lagares; Teresa Gómez del Pulgar; Eva Bandrés; Jesús García-Foncillas; Juan Carlos Lacal
Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy.
The international journal of biochemistry & cell biology 2008;40(9):1753-63.
2008: Carolina Espina; María Virtudes Céspedes; Miguel Angel García-Cabezas; María Teresa Gómez del Pulgar; Alicia Boluda; Lourdes García Oroz; Salvador A Benitah; Paloma Cejas; Manuel Nistal; Bafalluy Mangues; Juan Carlos Lacal
A critical role for Rac1 in tumor progression of human colorectal adenocarcinoma cells.
The American journal of pathology 2008;172(1):156-66.
2007: Ana Ramírez de Molina; Jacinto Sarmentero-Estrada; Cristóbal Belda-Iniesta; Miquel Tarón; Victor Ramírez de Molina; Paloma Cejas; Marcin Skrzypski; David Gallego-Ortega; Javier De Castro; Enrique Casado; Miguel Angel García-Cabezas; José Javier Sánchez; Manuel Nistal; Rafael Rosell; Manuel González Barón; Juan Carlos Lacal
Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study.
The lancet oncology 2007;8(10):889-97.
2007: María Virtudes Céspedes; Carolina Espina; Miguel Angel García-Cabezas; Manuel Trias; Alicia Boluda; María Teresa Gómez del Pulgar; Francesc Josep Sancho; Manuel Nistal; Juan Carlos Lacal; Bafalluy Mangues
Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites.
The American journal of pathology 2007;170(3):1077-85.
2007: Teresa Gómez del Pulgar; Eva Bandrés; Carolina Espina; Fátima Valdés-Mora; Rosa Pérez-Palacios; Fermín García-Amigot; Jesús García-Foncillas; Juan Carlos Lacal
Differential expression of Rac1 identifies its target genes and its contribution to progression of colorectal cancer.
The international journal of biochemistry & cell biology 2007;39(12):2289-302.
2006: David Gallego-Ortega; Ana Ramirez de Molina; Ruth Gutierrez; Maria Angeles Ramos; Jacinto Sarmentero; Paloma Cejas; Manuel Nistal; Manuel González Barón; Juan Carlos Lacal
Generation and characterization of monoclonal antibodies against choline kinase alpha and their potential use as diagnostic tools in cancer.
International journal of oncology 2006;29(2):335-40.
2006: Christian M Matter; Matthias T Wyss; Patricia Meier; Nicolas Späth; Tobias von Lukowicz; Christine Lohmann; Bruno Weber; Ana Ramirez de Molina; Juan Carlos Lacal; Simon M Ametamey; Gustav K von Schulthess; Thomas F Lüscher; Philipp A Kaufmann; Alfred Buck
18F-choline images murine atherosclerotic plaques ex vivo.
Arteriosclerosis, thrombosis, and vascular biology 2006;26(3):584-9.
2006: Nada M S Al-Saffar; Helen Troy; Ana Ramírez de Molina; Laura E Jackson; Basetti Madhu; John R Griffiths; Martin Leach; Paul Workman; Juan Carlos Lacal; Ian R Judson; Yuen-Li Chung
Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.
Cancer research 2006;66(1):427-34.
2005: Ana Ramírez de Molina; David Gallego-Ortega; Jacinto Sarmentero; Mónica Bañez-Coronel; Yolanda Martín-Cantalejo; Juan Carlos Lacal
Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis.
Cancer research 2005;65(13):5647-53.
2005: Teresa Gómez del Pulgar; Salvador Aznar Benitah; Pilar F Valerón; Carolina Espina; Juan Carlos Lacal
Rho GTPase expression in tumourigenesis: evidence for a significant link.
BioEssays : news and reviews in molecular, cellular and developmental biology 2005;27(6):602-13.
2005: Rosario M Sánchez-Martín; Joaquín M Campos; Ana Conejo-García; Olga Cruz-López; Mónica Báñez-Coronel; Agustín Rodríguez-González; Miguel A Gallo; Juan Carlos Lacal; Antonio Espinosa
Symmetrical bis-quinolinium compounds: new human choline kinase inhibitors with antiproliferative activity against the HT-29 cell line.
Journal of medicinal chemistry 2005;48(9):3354-63.
2005: Agustín Rodríguez-González; Ana Ramírez de Molina; Mónica Bañez-Coronel; Diego Megias; Juan Carlos Lacal
Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism.
International journal of oncology 2005;26(4):999-1008.
2004: Salvador Aznar Benitah; Pilar F Valerón; Linda van Aelst; Christopher J Marshall; Juan Carlos Lacal
Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation.
Biochimica et biophysica acta 2004;1705(2):121-32.
2004: Agustín Rodríguez-González; Ana Ramirez de Molina; Felix Fernández; Juan Carlos Lacal
Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action.
Oncogene 2004;23(50):8247-59.
2004: Ana Conejo-García; Mónica Báñez-Coronel; Rosario M Sánchez-Martín; Agustín Rodríguez-González; Angeles Ramos; Ana Ramírez de Molina; Antonio Espinosa; Miguel A Gallo; Joaquín M Campos; Juan Carlos Lacal
Influence of the linker in bispyridium compounds on the inhibition of human choline kinase.
Journal of medicinal chemistry 2004;47(22):5433-40.
2004: Mónica Báñez-Coronel; Agustín Rodríguez-González; Yolanda Martín-Cantalejo; Beatriz Sáez; Javier Soto; M Jesús Villa; Miguel F Braña; Juan Carlos Lacal
A novel 4,4'-bispyridyl-5,5'-perfluoroalkyl-2,2'-bisoxazol with antitumoral activity via cell cycle arrest and induction of apoptosis.
International journal of oncology 2004;25(4):1097-103.
2004: Ana Ramírez de Molina; Mónica Báñez-Coronel; Ruth Gutiérrez; Agustín Rodríguez-González; David Olmeda; Diego Megías; Juan Carlos Lacal
Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression.
Cancer research 2004;64(18):6732-9.
2004: Salvador Aznar; Pilar Fernández-Valerón; Carolina Espina; Juan Carlos Lacal
Rho GTPases: potential candidates for anticancer therapy.
Cancer letters 2004;206(2):181-91.
2004: Ana Ramírez de Molina; Agustín Rodríguez-González; Juan Carlos Lacal
From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design.
Cancer letters 2004;206(2):137-48.
2004: Miguel F Braña; Mónica Cacho; Mario A García; Beatriz de Pascual-Teresa; Ana Ramos; M Teresa Domínguez; José M Pozuelo; Cristina Abradelo; María Fernanda Rey-Stolle; Mercedes Yuste; Mónica Báñez-Coronel; Juan Carlos Lacal
New analogues of amonafide and elinafide, containing aromatic heterocycles: synthesis, antitumor activity, molecular modeling, and DNA binding properties.
Journal of medicinal chemistry 2004;47(6):1391-9.
2004: Pilar F Valerón; S Aznar-Benitah; Juan Carlos Lacal
Signal transduction and apoptosis pathways as therapeutic targets.
Progress in molecular and subcellular biology 2004;36():307-23.
2003: Agustín Rodríguez-González; Ana Ramírez de Molina; Félix Fernández; Maria Angeles Ramos; Maria del Carmen Núñez; Joaquín Campos; Juan Carlos Lacal
Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells.
Oncogene 2003;22(55):8803-12.
2003: Salvador Aznar Benitah; Pilar F Valerón; Juan Carlos Lacal
ROCK and nuclear factor-kappaB-dependent activation of cyclooxygenase-2 by Rho GTPases: effects on tumor growth and therapeutic consequences.
Molecular biology of the cell 2003;14(7):3041-54.
2003: Joaquín Campos; María C Núñez; Ana Conejo-García; Rosario M Sánchez-Martín; Rubén Hernández-Alcoceba; Agustín Rodríguez-González; Juan Carlos Lacal; Miguel A Gallo; Antonio Espinosa
QSAR-derived choline kinase inhibitors: how rational can antiproliferative drug design be?
Current medicinal chemistry 2003;10(13):1095-112.
2003: Juan Carlos Lacal; Amancio Carnero
Targeted search for anticancer drugs--CNIO cancer conference. 16-18 March, Madrid, Spain.
IDrugs : the investigational drugs journal 2003;6(5):437-41.
2003: Agustín Rodríguez-González; Ana Ramírez de Molina; Joaquín Benítez-Rajal; Juan Carlos Lacal
Phospholipase D and choline kinase: their role in cancer development and their potential as drug targets.
Progress in cell cycle research 2003;5():191-201.
2003: Ana Conejo-García; Joaquín Campos; Rosario M Sánchez; Agustín Rodríguez-González; Juan Carlos Lacal; Miguel A Gallo; Antonio Espinosa
Choline kinase inhibitory effect and antiproliferative activity of new 1,1',1"-(benzene-1,3,5-triylmethylene)tris[4-[(disubstituted)amino]pyridinium] tribromides.
European journal of medicinal chemistry 2003;38(1):109-16.
2003: Salvador Aznar Benitah; Pilar F Valerón; Hallgeir Rui; Juan Carlos Lacal
STAT5a activation mediates the epithelial to mesenchymal transition induced by oncogenic RhoA.
Molecular biology of the cell 2003;14(1):40-53.
2002: Luisa Lucas; Verónica Penalva; Ana Ramírez de Molina; Luis del Peso; Juan Carlos Lacal
Modulation of phospholipase D by Ras proteins mediated by its effectors Ral-GDS, PI3K and Raf-1.
International journal of oncology 2002;21(3):477-85.
2002: Ana Ramírez de Molina; Agustín Rodríguez-González; Ruth Gutiérrez; Luis Martínez-Piñeiro; José Sánchez; Félix Bonilla; Rafael Rosell; Juan Carlos Lacal
Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers.
Biochemical and biophysical research communications 2002;296(3):580-3.
2002: Isabel Sánchez-Pérez; Salvador Aznar Benitah; Montserrat Martínez-Gomariz; Juan Carlos Lacal; Rosario Perona
Cell stress and MEKK1-mediated c-Jun activation modulate NFkappaB activity and cell viability.
Molecular biology of the cell 2002;13(8):2933-45.
2002: Joaquín M Campos; María C Núñez; Rosario M Sánchez; José A Gómez-Vidal; Agustín Rodríguez-González; Mónica Báñez; Miguel A Gallo; Juan Carlos Lacal; Antonio Espinosa
Quantitative structure-activity relationships for a series of symmetrical bisquaternary anticancer compounds.
Bioorganic & medicinal chemistry 2002;10(7):2215-31.
2002: Ana Ramírez de Molina; Ruth Gutiérrez; Maria Angeles Ramos; José María Silva; Javier Silva; Félix Bonilla; José Javier Sánchez; Juan Carlos Lacal
Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy.
Oncogene 2002;21(27):4317-22.
2002: Ana Ramírez de Molina; Verónica Penalva; Luisa Lucas; Juan Carlos Lacal
Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K.
Oncogene 2002;21(6):937-46.
2001: Salvador Aznar; Pilar F Valerón; S V del Rincon; L F Pérez; Rosario Perona; Juan Carlos Lacal
Simultaneous tyrosine and serine phosphorylation of STAT3 transcription factor is involved in Rho A GTPase oncogenic transformation.
Molecular biology of the cell 2001;12(10):3282-94.
2001: Ana Ramírez de Molina; Agustín Rodríguez-González; Verónica Penalva; Luisa Lucas; Juan Carlos Lacal
Inhibition of ChoK is an efficient antitumor strategy for Harvey-, Kirsten-, and N-ras-transformed cells.
Biochemical and biophysical research communications 2001;285(4):873-9.
2001: Ana Ramírez de Molina; Agustín Rodríguez-González; Juan Carlos Lacal
Targeting new anticancer drugs within signalling pathways regulated by the Ras GTPase superfamily (Review).
International journal of oncology 2001;19(1):5-17.
2001: Salvador Aznar; Juan Carlos Lacal
Rho signals to cell growth and apoptosis.
Cancer letters 2001;165(1):1-10.
2001: Juan Carlos Lacal
Choline kinase: a novel target for antitumor drugs.
IDrugs : the investigational drugs journal 2001;4(4):419-26.
2001: Joaquín Campos; M del Carmen Núñez; V Rodríguez; Antonio Entrena; Rubén Hernández-Alcoceba; F Fernández; Juan Carlos Lacal; Miguel A Gallo; Antonio Espinosa
LUMO energy of model compounds of bispyridinium compounds as an index for the inhibition of choline kinase.
European journal of medicinal chemistry 2001;36(3):215-25.
2001: Luisa Lucas; Rubén Hernández-Alcoceba; Verónica Penalva; Juan Carlos Lacal
Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity.
Oncogene 2001;20(9):1110-7.
2001: Salvador Aznar; Juan Carlos Lacal
Searching new targets for anticancer drug design: the families of Ras and Rho GTPases and their effectors.
Progress in nucleic acid research and molecular biology 2001;67():193-234.
2000: N Embade; Pilar F Valerón; Salvador Aznar; E López-Collazo; Juan Carlos Lacal
Apoptosis induced by Rac GTPase correlates with induction of FasL and ceramides production.
Molecular biology of the cell 2000;11(12):4347-58.
2000: Luisa Lucas; Luis del Peso; P Rodríguez; Verónica Penalva; Juan Carlos Lacal
Ras protein is involved in the physiological regulation of phospholipase D by platelet derived growth factor.
Oncogene 2000;19(3):431-7.
1999: Rubén Hernández-Alcoceba; F Fernández; Juan Carlos Lacal
In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery.
Cancer research 1999;59(13):3112-8.
1999: Silvia Montaner; Rosario Perona; L Saniger; Juan Carlos Lacal
Activation of serum response factor by RhoA is mediated by the nuclear factor-kappaB and C/EBP transcription factors.
The Journal of biological chemistry 1999;274(13):8506-15.
1998: P Esteve; N Embade; Rosario Perona; B Jiménez; Luis del Peso; Javier León; M Arends; T Miki; Juan Carlos Lacal
Rho-regulated signals induce apoptosis in vitro and in vivo by a p53-independent, but Bcl2 dependent pathway.
Oncogene 1998;17(14):1855-69.
1998: Silvia Montaner; Rosario Perona; L Saniger; Juan Carlos Lacal
Multiple signalling pathways lead to the activation of the nuclear factor kappaB by the Rho family of GTPases.
The Journal of biological chemistry 1998;273(21):12779-85.
1998: Amancio Carnero; Juan Carlos Lacal
Wortmannin, an inhibitor of phosphatidyl-inositol 3-kinase, induces oocyte maturation through a MPF-MAPK-dependent pathway.
FEBS letters 1998;422(2):155-9.
1997: Luis del Peso; Rubén Hernández-Alcoceba; N Embade; Amancio Carnero; P Esteve; C Paje; Juan Carlos Lacal
Rho proteins induce metastatic properties in vivo.
Oncogene 1997;15(25):3047-57.
1997: Rubén Hernández-Alcoceba; L Saniger; Joaquín Campos; María C Núñez; F Khaless; Miguel A Gallo; Antonio Espinosa; Juan Carlos Lacal
Choline kinase inhibitors as a novel approach for antiproliferative drug design.
Oncogene 1997;15(19):2289-301.
1997: OA Coso; Silvia Montaner; C Fromm; Juan Carlos Lacal; R Prywes; Hidemi Teramoto; J Silvio Gutkind
Signaling from G protein-coupled receptors to the c-jun promoter involves the MEF2 transcription factor. Evidence for a novel c-jun amino-terminal kinase-independent pathway.
The Journal of biological chemistry 1997;272(33):20691-7.
1997: Juan Carlos Lacal
Regulation of proliferation and apoptosis by Ras and Rho GTPases through specific phospholipid-dependent signaling.
FEBS letters 1997;410(1):73-7.
1997: Luis del Peso; Luisa Lucas; P Esteve; Juan Carlos Lacal
Activation of phospholipase D by growth factors and oncogenes in murine fibroblasts follow alternative but cross-talking pathways.
The Biochemical journal 1997;322 ( Pt 2)():519-28.
1997: Rosario Perona; Silvia Montaner; L Saniger; Isabel Sánchez-Pérez; R Bravo; Juan Carlos Lacal
Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins.
Genes & development 1997;11(4):463-75.
1996: Luis del Peso; R Hernández; P Esteve; Juan Carlos Lacal
Activation of phospholipase D by ras proteins is independent of protein kinase C.
Journal of cellular biochemistry 1996;61(4):599-608.
1995: P Esteve; Luis del Peso; Juan Carlos Lacal
Induction of apoptosis by rho in NIH 3T3 cells requires two complementary signals. Ceramides function as a progression factor for apoptosis.
Oncogene 1995;11(12):2657-65.
1995: Amancio Carnero; Marek Liyanage; S Stabel; Juan Carlos Lacal
Evidence for different signalling pathways of PKC zeta and ras-p21 in Xenopus oocytes.
Oncogene 1995;11(8):1541-7.
1995: Silvia Montaner; A Ramos; Rosario Perona; P Esteve; Amancio Carnero; Juan Carlos Lacal
Overexpression of PKC zeta in NIH3T3 cells does not induce cell transformation nor tumorigenicity and does not alter NF kappa B activity.
Oncogene 1995;10(11):2213-20.
1995: B Jiménez; M Arends; P Esteve; Rosario Perona; R Sánchez; S Ramón y Cajal; A Wyllie; Juan Carlos Lacal
Induction of apoptosis in NIH3T3 cells after serum deprivation by overexpression of rho-p21, a GTPase protein of the ras superfamily.
Oncogene 1995;10(5):811-6.
1995: Amancio Carnero; Juan Carlos Lacal
Activation of intracellular kinases in Xenopus oocytes by p21ras and phospholipases: a comparative study.
Molecular and cellular biology 1995;15(2):1094-101.
1995: Ricado Sanchez-Prieto; Juan A Vargas; Amancio Carnero; E Marchetti; J Romero; A Durantez; Juan Carlos Lacal; Santiago Ramon Y Cajal
Modulation of cellular chemoresistance in keratinocytes by activation of different oncogenes.
International journal of cancer. Journal international du cancer 1995;60(2):235-43.
1995: B Jiménez; Luis del Peso; Silvia Montaner; P Esteve; Juan Carlos Lacal
Generation of phosphorylcholine as an essential event in the activation of Raf-1 and MAP-kinases in growth factors-induced mitogenic stimulation.
Journal of cellular biochemistry 1995;57(1):141-9.
1994: Amancio Carnero; B Jiménez; Juan Carlos Lacal
Progesterone but not ras requires MPF for in vivo activation of MAPK and S6 KII: MAPK is an essential conexion point of both signaling pathways.
Journal of cellular biochemistry 1994;55(4):465-76.
1994: Amancio Carnero; A Cuadrado; Luis del Peso; Juan Carlos Lacal
Activation of type D phospholipase by serum stimulation and ras-induced transformation in NIH3T3 cells.
Oncogene 1994;9(5):1387-95.
1994: Amancio Carnero; F Dolfi; Juan Carlos Lacal
ras-p21 activates phospholipase D and A2, but not phospholipase C or PKC, in Xenopus laevis oocytes.
Journal of cellular biochemistry 1994;54(4):478-86.
1993: A Cuadrado; Amancio Carnero; F Dolfi; B Jiménez; Juan Carlos Lacal
Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors.
Oncogene 1993;8(11):2959-68.
1993: F Dolfi; Amancio Carnero; A Cuadrado; G Ramponi; Juan Carlos Lacal
Acylphosphatase synergizes with progesterone during maturation of Xenopus laevis oocytes.
FEBS letters 1993;327(3):265-70.
1993: Amancio Carnero; Juan Carlos Lacal
Phospholipase-induced maturation of Xenopus laevis oocytes: mitogenic activity of generated metabolites.
Journal of cellular biochemistry 1993;52(4):440-8.
1993: F Dolfi; Amancio Carnero; G Ramponi; Juan Carlos Lacal
Microinjection of acylphosphatase blocks Xenopus laevis oocytes maturation induced by ras-p21.
FEBS letters 1993;326(1-3):167-70.
1993: Rosario Perona; P Esteve; B Jiménez; R P Ballestero; S Ramón y Cajal; Juan Carlos Lacal
Tumorigenic activity of rho genes from Aplysia californica.
Oncogene 1993;8(5):1285-92.
1990: Juan Carlos Lacal; A Cuadrado; J E Jones; R Trotta; D E Burstein; T Thomson; Angel Pellicer
Regulation of protein kinase C activity in neuronal differentiation induced by the N-ras oncogene in PC-12 cells.
Molecular and cellular biology 1990;10(6):2983-90.
1990: R J Trotta; T M Thomson; Juan Carlos Lacal; Angel Pellicer; D E Burstein
Potentiation of oncogenic N-ras-induced neurite outgrowth and ornithine decarboxylase activity by phorbol dibutyrate and protein kinase inhibitor H-8.
Journal of cellular physiology 1990;143(1):68-78.
1990: Juan Carlos Lacal
Diacylglycerol production in Xenopus laevis oocytes after microinjection of p21ras proteins is a consequence of activation of phosphatidylcholine metabolism.
Molecular and cellular biology 1990;10(1):333-40.
1990: Rafael Fridman; Juan Carlos Lacal; Reuven Reich; R Daniel Bonfil; C H Ahn
Differential effects of phorbol ester on the in vitro invasiveness of malignant and non-malignant human fibroblast cells.
Journal of cellular physiology 1990;142(1):55-60.
1988: A Valencia; L Serrano; R Caballero; P S Anderson; Juan Carlos Lacal
Conformational alterations detected by circular dichroism induced in the normal ras p21 protein by activating point mutations at position 12, 59, or 61.
European journal of biochemistry / FEBS 1988;174(4):621-7.